CN114617792B - Anti-aging composition, preparation method and application thereof, and anti-aging skin care product - Google Patents
Anti-aging composition, preparation method and application thereof, and anti-aging skin care product Download PDFInfo
- Publication number
- CN114617792B CN114617792B CN202210309547.4A CN202210309547A CN114617792B CN 114617792 B CN114617792 B CN 114617792B CN 202210309547 A CN202210309547 A CN 202210309547A CN 114617792 B CN114617792 B CN 114617792B
- Authority
- CN
- China
- Prior art keywords
- aging
- sodium hyaluronate
- madecassoside
- alanyl
- enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to an anti-aging composition, a preparation method and application thereof, and an anti-aging skin care product, wherein the anti-aging composition comprises the following components in parts by mass: 0.1 to 0.8 portion of madecassoside, 0.1 to 8 portions of enzyme-digested sodium hyaluronate and 0.01 to 0.1 portion of beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine. The madecassoside, the enzyme-digested sodium hyaluronate and the beta-alanyl hydroxy prolyl diaminobutyric benzylamine are synergistic according to a specific proportion, so that the procollagen protein and the elastin protein can be effectively protected, and new collagen protein and elastin protein can be supplemented; the protection and supplement of the collagen and the elastin are organically combined, so that the thickness of a dermis layer is effectively increased, the elasticity of the skin is kept, and the anti-aging effect is effectively improved; and the emulsifier is not required to be additionally added for assisting dissolution, so that the product is mild and has no stimulation.
Description
Technical Field
The invention relates to the technical field of cosmetics, in particular to an anti-aging composition, a preparation method and application thereof, and an anti-aging skin care product.
Background
Aging, also known as aging, is the process of loss and degeneration of the organism from constitutional substances, tissue structures to physiological functions and gradual death of the organism with the lapse of time or the increase of age; is a complex and irreversible natural phenomenon. Skin aging is a direct manifestation of aging, mainly manifested by wrinkle hyperplasia, skin dryness and atrophy, pigmentation, loss of elasticity, and the like. Skin aging not only affects the beauty of the face, but also may cause psychological problems such as depression and self-disfigurement. Therefore, finding an ideal cosmetic against skin aging is one of the hot spots of the current research.
In the traditional cosmetics for resisting skin aging, fat-soluble substances with anti-aging effect are generally added, so that an emulsifier is required to ensure the stability of the system. The metabolism of the aged skin is reduced, the active enzymes in the body are reduced, and the emulsifier added in the cosmetics can cause damage and burden to the aged skin. The vitamin A and the derivatives thereof can stimulate the proliferation of fibroblasts and supplement collagen and elastin of the skin, and are widely applied to anti-aging skin care products. However, vitamin a and its derivatives are apt to cause skin irritation and adverse reactions, and even cause symptoms such as redness, stabbing pain, desquamation and the like in severe cases.
Therefore, the anti-aging composition which does not need to add an emulsifier, has good anti-aging effect and is mild and non-irritant is of great significance.
Disclosure of Invention
Based on the above, the invention provides the anti-aging composition which is free of adding an emulsifier, good in anti-aging effect, mild and non-irritant, the preparation method and the application thereof, and the anti-aging skin care product.
The technical scheme of the invention for solving the technical problems is as follows.
An anti-aging composition comprises the following components in parts by weight:
0.1 to 0.8 portion of madecassoside;
enzyme-cutting 0.1-8 parts of sodium hyaluronate; and
beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine 0.01-0.1 weight portions.
In some embodiments, the anti-aging composition comprises the following components in parts by weight:
0.1 to 0.5 portion of madecassoside;
enzyme-digested sodium hyaluronate 0.25-4 parts;
beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine 0.01-0.05 part.
In some embodiments, the anti-aging composition comprises the following components in parts by weight:
0.2 to 0.5 portion of madecassoside;
1-4 parts of enzyme-digested sodium hyaluronate;
beta-alanyl hydroxy prolyl diamino butyric benzylamine 0.01-0.05 weight portions.
In some embodiments, the anti-aging composition has a mass ratio of the madecassoside to the enzyme-cleaved sodium hyaluronate (0.075-8): 1.
In some embodiments, the anti-aging composition comprises the beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine and the enzyme-cleaved sodium hyaluronate in a mass ratio of (0.009-1): 1.
The invention provides application of the anti-aging composition in preparation of skin care products or medicines.
The invention provides a skin care product which comprises the anti-aging composition and a solvent or a matrix acceptable in the skin care product.
In some embodiments, the skin care product is a cleansing product, a facial mask product, a cream, a serum, a toner, or an emulsion.
The invention provides toner which comprises a solvent, a humectant, a preservative and the anti-aging composition.
The invention provides a medicine, which comprises the anti-aging composition and auxiliary materials or matrixes acceptable in the medicine.
Compared with the prior art, the anti-aging composition has the following beneficial effects:
the anti-aging composition comprises madecassoside, enzyme-digested sodium hyaluronate and beta-alanyl hydroxyproline diaminobutyric benzylamine in a specific ratio; the enzyme-digested sodium hyaluronate can effectively promote the proliferation of fibroblasts, and the generation of collagen and elastin can be promoted from the source; matching with madecassoside and beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine to promote the generation of type I and type III collagen, thereby further improving the content of collagen and elastin in the dermis and keeping the skin elasticity; meanwhile, the madecassoside is matched with beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine to effectively inhibit the generation of MMPs and the activity of elastase, thereby reducing the loss of collagen and the denaturation of elastin. By the synergistic action of madecassoside, enzyme-cleaved sodium hyaluronate and beta-alanyl hydroxyprolyl diaminobutyric acid benzylamine according to a specific proportion, procollagen and elastin can be effectively protected, and new collagen and elastin can be supplemented; the protection and supplement of the collagen and the elastin are organically combined, so that the thickness of a dermis layer is effectively increased, the elasticity of the skin is kept, and the anti-aging effect is effectively improved.
In addition, the madecassoside, the enzyme-digested sodium hyaluronate and the beta-alanyl hydroxy prolyl diaminobutyric benzylamine belong to skin conditioners, are mild and non-irritant, and have extremely high safety; and the anti-aging composition is easy to dissolve in water, and an emulsifier is not required to be additionally added for assisting dissolution, so that the safety performance of the anti-aging composition is further improved.
Detailed Description
The technical solution of the present invention will be described in further detail with reference to specific examples. The present invention may be embodied in many different forms and is not limited to the embodiments described herein. It is to be understood that these embodiments are provided so that this disclosure will be thorough and complete.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items.
In the description of the present invention, "a plurality" means two or more unless specifically defined otherwise.
The weight of the related components mentioned in the description of the embodiments of the present invention may not only refer to the specific content of each component, but also represent the proportional relationship of the weight among the components, and therefore, the content of the related components is scaled up or down within the scope disclosed in the description of the embodiments of the present invention as long as it is in accordance with the description of the embodiments of the present invention. Specifically, the weight described in the description of the embodiment of the present invention may be a unit of mass known in the chemical industry field, such as μ g, mg, g, and kg.
The researchers of the invention research how to effectively resist aging, and the skin is obtained by analysis and consists of epidermis, dermis and subcutaneous tissues; wherein, the outermost epidermis is composed of flat and columnar keratinocyte mosaics; the subcutaneous tissue is in direct contact with the muscle, the last layer of skin; the middle dermal layer is composed mainly of extracellular matrix (ECM) synthesized by fibroblasts, which is a complex structure composed of collagen, elastic fibers, reticular fibers, and proteoglycans. With age, fibroblast activity decreases, and synthetic collagen and elastin decrease; meanwhile, the metalloprotease MMPs and elastase in a high-activity state can cause collagen loss and elastin denaturation, accelerate skin aging, and enable the skin to lose elasticity, have large pores and grow wrinkles.
Based on this, the researchers of the present invention focus on the anti-aging of the dermis, and from the supplement and protection of collagen and elastin, the researchers can promote the production of collagen and elastin by promoting the proliferation of fibroblasts, and simultaneously reduce the loss of collagen and the inactivation of elastin by inhibiting the activity of metalloprotease and elastase, thereby achieving the anti-aging effect from the source.
The invention provides an anti-aging composition which comprises the following components in parts by mass:
0.1 to 0.8 portion of madecassoside;
enzyme-cutting 0.1-8 parts of sodium hyaluronate;
beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine 0.01-0.1 weight portions.
It is understood that the madecassoside can be 0.1 parts, 0.2 parts, 0.3 parts, 0.4 parts, 0.5 parts, 0.6 parts, 0.7 parts, 0.8 parts, etc.; the enzyme-digested sodium hyaluronate can be 0.1 part, 0.5 part, 1 part, 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts and the like; beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine can be 0.01 part, 0.025 part, 0.04 part, 0.05 part, 0.1 part, etc.
The anti-aging composition comprises madecassoside, enzyme-digested sodium hyaluronate and beta-alanyl hydroxyproline diaminobutyric benzylamine in a specific ratio; the enzyme-digested sodium hyaluronate can effectively promote the proliferation of fibroblasts, and the generation of collagen and elastin is promoted from the source; the combination of madecassoside and beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine promotes the generation of type I and type III collagen, thereby further increasing the content of collagen and elastin in the dermis and keeping the skin elasticity; meanwhile, the madecassoside is matched with beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine to effectively inhibit the generation of MMPs and the activity of elastase, thereby reducing the loss of collagen and the denaturation of elastin.
In addition, the madecassoside, the enzyme-digested sodium hyaluronate and the beta-alanyl hydroxyprolyl diaminobutyric acid benzylamine belong to skin conditioners, are mild and non-irritant, and have extremely high safety; and the anti-aging composition is easy to dissolve in water, and an emulsifier is not required to be additionally added for assisting dissolution, so that the safety performance of the anti-aging composition is further improved.
Madecassoside
Centella asiatica is a plant of centella in Umbelliferae, dry whole plant of centella asiatica is listed as middle-grade product from Shen nong Ben Cao Jing, which is named as Daidao, dazhuan, zaumaocao, dayeqian, etc., is a creeping herb for many years, is sweet, pungent and cool, and has the effects of clearing heat and promoting diuresis, detoxifying and diminishing swelling, and activating blood and stopping bleeding.
Madecassoside (MC) is one of the main components of triterpenoid saponin in centella asiatica extract, and has multiple chemical groups such as hydroxyl group and steroid ring. The madecassoside can promote the synthesis of type I and type III collagen, promote the secretion of mucopolysaccharide, increase the water retention of skin, activate and renew skin cells, and make skin smooth, bright and smooth.
Matrix Metalloproteinases (MMPs) are one of the most important proteases causing the destruction of matrix components, and are also proteases essential for the apoptotic process. The madecassoside can inhibit the activity of MMP-1 and other MMPs to a certain extent, thereby reducing the loss of collagen in the skin matrix.
Enzyme-digested sodium hyaluronate (enzyme-digested HA)
Hyaluronic Acid (HA) is a high molecular polymer of disaccharide unit composed of D-glucuronic acid and N-acetylglucosamine, and HAs a molecular formula of (C) 14 H 21 NO 11 ) n is the same as the formula (I). The enzyme digestion HA is small molecular sodium hyaluronate with ultrahigh biological activity and molecular weight between 400Da and 1000Da which is obtained by adopting an enzyme digestion process and a spray drying process/freeze drying process; the enzyme-digested HA can rapidly penetrate the epidermis, reach the dermis layer, remove free radicals, and promote the proliferation of fibroblasts.
Beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine
Introducing a hydroxyl group into a Dipeptide diaminobutyryl benzamide diacetate heterocyclic ring, namely, changing proline of the Dipeptide diaminobutyryl benzamide diacid into hydroxyproline to obtain beta-alanyl hydroxyproline diaminobutyric acid benzylamine. The beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine can promote the synthesis of type I collagen, thereby realizing endogenous collagen supplementation, and playing the roles of repairing and caring skin, improving skin aging and solving skin relaxation. Meanwhile, the beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine can inhibit elastase and reduce the degradation of elastase on elastin, thereby protecting elastin, enhancing the supporting force of dermis and realizing the efficacy of anti-aging.
By the synergistic action of madecassoside, enzyme-cleaved sodium hyaluronate and beta-alanyl hydroxyprolyl diaminobutyric acid benzylamine according to a specific proportion, procollagen and elastin can be effectively protected, and new collagen and elastin can be supplemented; the protection and supplement of the collagen and the elastin are organically combined, so that the thickness of a dermis layer is effectively increased, the elasticity of the skin is kept, and the anti-aging effect is effectively improved.
In some examples, the anti-aging composition comprises the following components in parts by weight:
0.1 to 0.5 portion of madecassoside;
enzyme-cutting 0.25-4 parts of sodium hyaluronate;
beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine 0.01-0.05 part.
In some examples, the anti-aging composition comprises the following components in parts by weight:
0.2 to 0.5 portion of madecassoside;
1-4 parts of enzyme-digested sodium hyaluronate;
beta-alanyl hydroxy prolyl diamino butyric benzylamine 0.01-0.05 weight portions.
In some examples, the anti-aging composition comprises the following components in parts by weight:
0.2 to 0.5 portion of madecassoside;
2-4 parts of enzyme-digested sodium hyaluronate;
beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine 0.025-0.05 part.
In some examples, the anti-aging composition comprises the following components in parts by weight:
0.4 to 0.5 portion of madecassoside;
2-4 parts of enzyme-digested sodium hyaluronate;
beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine 0.04-0.05 part.
In some examples, the anti-aging composition comprises the following components in parts by weight:
0.5 part of madecassoside;
4 parts of enzyme-digested sodium hyaluronate;
beta-alanyl hydroxy prolyl diamino butyric benzylamine 0.05 weight portions.
In some examples, the anti-aging composition has a mass ratio of the madecassoside to the enzyme-cleaved sodium hyaluronate (0.075-8): 1; optionally, the mass ratio of the madecassoside to the enzyme-digested sodium hyaluronate is (0.1-2): 1.
In some specific examples, the anti-aging composition has a mass ratio of the madecassoside to the enzyme-cleaved sodium hyaluronate (0.1-0.4): 1; optionally, the mass ratio of the madecassoside to the enzyme-digested sodium hyaluronate is (0.1-0.25): 1; furthermore, the mass ratio of the madecassoside to the enzyme-digested sodium hyaluronate is 0.1.
In some examples, the anti-aging composition has the mass ratio of beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine to enzyme-cleaved sodium hyaluronate (0.009-1): 1; optionally, the mass ratio of the beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine to the enzyme-digested sodium hyaluronate is (0.01-0.04): 1; furthermore, the mass ratio of beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine to enzyme-cleaved sodium hyaluronate (0.0125-0.025) is 1.
In some preferred examples, the anti-aging composition has a mass ratio of β -alanyl hydroxyproline diaminobutyric acid benzylamine to enzymatically cleaved sodium hyaluronate of 0.0125.
One embodiment of the invention provides a preparation method of an anti-aging composition, which comprises the following steps:
preparing raw materials according to the components of the anti-aging composition;
mixing madecassoside, enzyme-cleaved sodium hyaluronate and beta-alanyl hydroxyprolyl diaminobutyric benzylamine.
The invention provides an application of the anti-aging composition in preparation of skin care products or medicines.
One embodiment of the present invention provides a skin care product, which comprises the anti-aging composition and a solvent or matrix acceptable in the skin care product.
In some examples, the skin care product is a cleansing product, a mask product, a cream, a essence, a toner, or an emulsion.
The invention provides toner, which comprises a solvent, a humectant, a preservative and the anti-aging composition.
In some of these examples, the solvent is water.
In some of these examples, the emollient water and the humectant is selected from at least one of 1, 2-pentanediol and 1, 2-hexanediol.
In some of these examples, the preservative is p-hydroxyacetophenone in the toner.
In some specific examples, the anti-aging composition, 1, 2-pentanediol, 1, 2-hexanediol, p-hydroxyacetophenone, and water are contained in the toner.
In some examples, the toner comprises the following components in parts by weight:
further, 0.2 to 0.6 portion of 1, 2-pentanediol, 0.6 to 0.8 portion of 1, 2-hexanediol and 0.25 to 0.5 portion of p-hydroxyacetophenone; optionally, 0.7-0.8 part of 1, 2-pentanediol, 0.07-0.8 part of 1, 2-hexanediol and 0.25-0.5 part of p-hydroxyacetophenone.
In some preferred examples, the toner comprises the following components in parts by weight: 0.4 part of madecassoside, 4 parts of enzyme-digested sodium hyaluronate, 0.05 part of beta-alanyl hydroxy prolyl diaminobutyric benzylamine, 0.4 part of 1, 2-pentanediol, 0.8 part of 1, 2-hexanediol and 0.5 part of p-hydroxyacetophenone.
The invention provides a preparation method of toner, which comprises the following steps:
mixing madecassoside, enzyme-cleaved sodium hyaluronate, beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine, 1, 2-pentanediol, 1, 2-hexanediol, p-hydroxyacetophenone and water.
In some examples, the preparation method of the toner comprises the following steps:
uniformly mixing beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine, 1, 2-pentanediol, 1, 2-hexanediol (1/20-1/10 of the total amount) and water to obtain a mixed solution of the beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine;
uniformly mixing enzyme-digested sodium hyaluronate, p-hydroxyacetophenone (1/10-1/2 of the total amount) and 1, 2-hexanediol (1/15-1/5 of the total amount) with water to obtain an enzyme-digested sodium hyaluronate mixed solution;
mixing madecassoside with the rest 1, 2-hexanediol, p-hydroxyacetophenone and water to obtain madecassoside water solution;
the mixed solution of beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine, the mixed solution of enzyme-digested sodium hyaluronate and the aqueous solution of madecassoside are mixed evenly.
In some of these examples, the anti-aging skin care product is a cream. Further, the cream comprises the anti-aging composition, and cetostearyl alcohol, squalane, jojoba seed oil, hydrogenated lecithin, ammonium acryloyldimethyl taurate/VP copolymer, hexanediol, butanediol, glycerol and the like.
One embodiment of the present invention provides a pharmaceutical product, which comprises the above anti-aging composition and pharmaceutically acceptable adjuvants or bases.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
Hereinafter, the anti-aging composition, the preparation method and the application thereof, and the anti-aging skin care product according to the present invention are exemplified, and it is understood that the anti-aging composition, the preparation method and the application thereof, and the anti-aging skin care product according to the present invention are not limited to the following examples.
Example 1
Preparation of raw materials (100 parts in total):
0.1 part of madecassoside, 0.25 part of enzyme-digested sodium hyaluronate, 0.01 part of beta-alanyl hydroxy prolyl diaminobutyric benzylamine, 0.08 part of 1, 2-pentanediol, 0.64 part of 1, 2-hexanediol and 0.4 part of p-hydroxyacetophenone, and the balance of water (98.42 parts);
uniformly mixing beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine, 1, 2-pentanediol, 0.04 part (1/16 of the total amount) of 1, 2-hexanediol and one third of water to obtain a mixed solution of the beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine;
uniformly mixing enzyme-cleaved sodium hyaluronate, 0.0625 part (5/32 of the total amount) of p-hydroxyacetophenone and 0.075 part (17/128 of the total amount) of 1, 2-hexanediol with one third of water to obtain enzyme-cleaved sodium hyaluronate mixed solution;
mixing madecassoside with the rest 1, 2-hexanediol, p-hydroxyacetophenone and water to obtain madecassoside water solution;
and uniformly mixing the beta-alanyl hydroxyproline diaminobutyric acid benzylamine mixed solution, the enzyme-cleaved sodium hyaluronate mixed solution and the madecassoside aqueous solution to obtain the anti-aging toner.
Example 2
The same as example 1, except that the ratio of the raw materials of the anti-aging toner was different as follows:
raw materials (total 100 parts):
0.2 portion of madecassoside, 1 portion of enzyme-cutting sodium hyaluronate, 0.01 portion of beta-alanyl hydroxy prolyl diaminobutyric benzylamine, 0.08 portion of 1, 2-pentanediol, 0.64 portion of 1, 2-hexanediol, 0.5 portion of p-hydroxyacetophenone and the balance of water.
Example 3
The same as example 1, except that the ratio of the raw materials of the anti-aging toner is different, specifically as follows:
raw materials (total 100 parts):
0.2 portion of madecassoside, 2 portions of enzyme-cutting sodium hyaluronate, 0.025 portion of beta-alanyl hydroxy prolyl diaminobutyric benzylamine, 0.2 portion of 1, 2-pentanediol, 0.7 portion of 1, 2-hexanediol, 0.5 portion of p-hydroxyacetophenone and the balance of water.
Example 4
The same as example 1, except that the ratio of the raw materials of the anti-aging toner is different, specifically as follows:
raw materials (total 100 parts):
0.5 part of madecassoside, 2 parts of enzyme-digested sodium hyaluronate, 0.05 part of beta-alanyl hydroxy prolyl diaminobutyric benzylamine, 0.4 part of 1, 2-pentanediol, 0.8 part of 1, 2-hexanediol, 0.25 part of p-hydroxyacetophenone and the balance of water.
Example 5
The same as example 1, except that the ratio of the raw materials of the anti-aging toner is different, specifically as follows:
raw materials (total 100 parts):
0.5 portion of madecassoside, 4 portions of restriction enzyme sodium hyaluronate, 0.05 portion of beta-alanyl hydroxy prolyl diaminobutyric benzylamine, 0.4 portion of 1, 2-pentanediol, 0.8 portion of 1, 2-hexanediol and 0.5 portion of p-hydroxyacetophenone, and the balance of water.
Example 6
The same as example 1, except that the ratio of the raw materials of the anti-aging toner is different, specifically as follows:
raw materials (total 100 parts):
0.4 portion of madecassoside, 4 portions of enzyme-cutting sodium hyaluronate, 0.05 portion of beta-alanyl hydroxy prolyl diaminobutyric benzylamine, 0.4 portion of 1, 2-pentanediol, 0.8 portion of 1, 2-hexanediol, 0.5 portion of p-hydroxyacetophenone and the balance of water.
Example 7
The same as example 1, except that the ratio of the raw materials of the anti-aging toner is different, specifically as follows:
raw materials (total 100 parts):
0.6 part of madecassoside, 8 parts of enzyme-digested sodium hyaluronate, 0.075 part of beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine, 0.6 part of 1, 2-pentanediol, 1.5 parts of 1, 2-hexanediol, 1 part of p-hydroxyacetophenone and the balance of water.
Example 8
The same as example 1, except that the ratio of the raw materials of the anti-aging toner is different, specifically as follows:
raw materials (total 100 parts):
0.8 portion of madecassoside, 0.1 portion of enzyme-digested sodium hyaluronate, 0.1 portion of beta-alanyl hydroxy prolyl diaminobutyric benzylamine, 0.8 portion of 1, 2-pentanediol, 0.8 portion of 1, 2-hexanediol, 0.5 portion of p-hydroxyacetophenone and the balance of water.
Comparative example 1
The anti-aging toner is basically the same as the anti-aging toner in example 3, except that the anti-aging toner is prepared from the following raw materials:
raw materials (total 100 parts):
0.2 portion of madecassoside, 0.2 portion of 1, 2-pentanediol, 0.4 portion of 1, 2-hexanediol and 0.25 portion of p-hydroxyacetophenone, and the balance of water.
Comparative example 2
The anti-aging toner is basically the same as that in example 3, except that the raw materials of the anti-aging toner are different, and are as follows:
raw materials (total 100 parts):
1 part of enzyme-digested sodium hyaluronate, 0.2 part of 1, 2-pentanediol, 0.4 part of 1, 2-hexanediol and 0.25 part of p-hydroxyacetophenone, and the balance of water.
Comparative example 3
The anti-aging toner is basically the same as the anti-aging toner in example 3, except that the anti-aging toner is prepared from the following raw materials:
raw materials (total 100 parts):
0.2 portion of madecassoside, 0.01 portion of beta-alanyl hydroxy prolyl diaminobutyric benzylamine, 0.2 portion of 1, 2-pentanediol, 0.4 portion of 1, 2-hexanediol and 0.25 portion of p-hydroxyacetophenone, and the balance of water.
Comparative example 4
The anti-aging toner is basically the same as that in example 3, except that the raw materials of the anti-aging toner are different, and are as follows:
raw materials (total 100 parts):
0.2 portion of madecassoside, 1 portion of enzyme-digested sodium hyaluronate, 0.2 portion of 1, 2-pentanediol, 0.4 portion of 1, 2-hexanediol and 0.25 portion of p-hydroxyacetophenone, and the balance of water.
Comparative example 5
The anti-aging toner is basically the same as that in example 3, except that the raw materials of the anti-aging toner are different, and are as follows:
raw materials (total 100 parts):
1 part of madecassoside, 0.005 part of enzyme-digested sodium hyaluronate, 0.005 part of beta-alanyl hydroxy prolyl diaminobutyric benzylamine, 0.2 part of 1, 2-pentanediol, 0.4 part of 1, 2-hexanediol, 0.25 part of p-hydroxyacetophenone and the balance of water.
Comparative example 6
The anti-aging toner is basically the same as the anti-aging toner in example 3, except that the anti-aging toner is prepared from the following raw materials:
raw materials (total 100 parts):
0.1 part of madecassoside, 0.25 part of enzyme-digested sodium hyaluronate, 0.01 part of snake venom tripeptide, 0.2 part of 1, 2-pentanediol, 0.4 part of 1, 2-hexanediol and 0.25 part of p-hydroxyacetophenone, and the balance of water.
Comparative example 7
The anti-aging toner is basically the same as that in example 3, except that the raw materials of the anti-aging toner are different, and are as follows:
raw materials (total 100 parts):
centella asiatica extract 0.1 parts, enzyme-digested sodium hyaluronate 0.25 parts, beta-alanyl hydroxy prolyl diaminobutyric benzylamine 0.01 parts, 1, 2-pentanediol 0.2 parts, 1, 2-hexanediol 0.4 parts, p-hydroxyacetophenone 0.25 parts, and water in balance.
The components and proportions of the anti-aging toner in each example and comparative example are shown in Table 1.
TABLE 1
Wherein a is snake venom tripeptide, and b is centella asiatica extract.
The anti-aging toner prepared in each example and comparative example was subjected to efficacy test:
1. skin firmness
1) Principle of testing
The skin firmness is tested by adopting a skin elasticity tester Cutomer dual MPA 580.
Skin firmness means that the skin is elastic and filled with collagen. The increase and decrease of skin firmness are closely related to skin elasticity and collagen content in skin. When the skin is loose and collagen is lost, the value of the skin tightness is high, and when the skin is elastic and filled with collagen, the value of the skin tightness is reduced.
2) Test method
And (3) testing environment: the temperature is 22 +/-1 ℃, the humidity is 50 +/-5%, and real-time dynamic detection is carried out;
test volunteers: age between 30-49 years (excluding pregnant or lactating women); patients without severe systemic disease, immunodeficiency or autoimmune disease; those who have no history of severe allergy to skin care cosmetics in the past; hormone drugs and immunosuppressants have not been used in the last month; those who did not participate in other clinical trials; the tested drugs are used according to the regulations and the data are complete; all volunteers filled out informed consent prior to testing.
Preparation before testing: no product (cosmetic or topical medicine) was used 2-3 days before the test site.
And (3) testing process: the subjects cleaned their faces in a constant temperature and humidity room and sat still for 30 minutes, and their cheek skin firmness was measured as the original value. Then according to daily use habits, the product is taken and smeared on the whole face, the face is gently massaged until the product is completely absorbed, then the product use instruction is carried out, the product is released for subsequent use, the test subject needs to use the product once in the morning and at night every day, the use lasts for 28 days, and then the test is carried out again after returning to a laboratory. The test of the same volunteer was performed by the same measurement staff.
3) Test results
The calculation formula of the skin compactness improvement rate is as follows: f% = (F) 1 -F 2 )/F1*100％
Wherein F is the skin firmness improvement rate,%;
F 1 is the skin firmness original value before use of the sample;
F 2 skin firmness after 28 days for continued use of the sample;
the results of skin firmness improvement rates measured using the toners prepared in each of examples and comparative examples are shown in table 2.
TABLE 2
As can be seen from table 2, the anti-aging compositions provided in the examples reduce the skin firmness to different degrees, laterally reflecting the increased skin elasticity and the increased collagen content of the skin of the subject, compared to the comparative ratio.
2. Roughness of skin
1) Principle of testing
The invention adopts a skin texture imager Visioscan VC20 plus for detecting the roughness parameter SEr, and the larger the measurement value is, the smoother the skin is. The skin roughness is an important index which objectively reflects the skin state and the skin aging degree, and the statistics of the results before and after the skin roughness can scientifically evaluate the skin care performance of the cosmetics.
2) After the skin firmness was tested as described above, the skin roughness was tested directly.
3) Test results
The skin roughness parameter SEr improvement rate calculation formula: r% = (R) 2 -R 1 )/R 1 *100％；
Wherein, R is the improvement rate of skin roughness,%;
R 2 skin roughness parameter SEr for the continued use of the sample after 28 days;
R 1 the original value of the SEr parameter of the skin roughness before the sample is used;
the results of the improvement rate of skin roughness parameter SEr measured using the toners obtained in each of examples and comparative examples are shown in Table 3.
TABLE 3
As can be seen from Table 3, the anti-aging compositions provided in the examples improve the skin roughness parameter SEr to a different extent than the comparative examples, indicating that the skin roughness is improved after the anti-aging toner prepared in the examples is used.
3. Thickness of dermis layer
1) Principle of testing
The CK UC22 skin ultrasonic instrument is used for detecting the thickness of the dermis layer, and the larger the measured value is, the larger the skin thickness is. The thickness of the dermis is an important index which objectively reflects the skin aging degree and the state of the extracellular matrix, and the statistics of the previous and subsequent results can scientifically evaluate the skin care performance of the cosmetics.
2) After testing the skin roughness as described above, the dermal layer thickness was tested directly.
3) Test results
The dermal layer thickness improvement rate calculation formula: t% = (T) 2 -T 1 )/T 1 *100％
Note: t is the improvement rate of the thickness of the dermis layer,%;
T 2 is the thickness of the dermis layer 28 days after using the sample;
T 1 the original value of the thickness of the front dermis layer of the sample is used;
the results of measuring the thickness of the dermis layer using the toners obtained in each of examples and comparative examples are shown in Table 4.
TABLE 4
As can be seen from table 4, each example provides an anti-aging composition that increases the thickness of the dermis layer to a different degree than the comparative example.
By comparing the skin firmness improvement rate, the skin roughness parameter SEr improvement rate and the dermis thickness improvement rate between comparative examples 2 and 3 and example 3, it can be seen that the anti-aging composition of the invention has a synergistic effect among the components, and when some components are absent, the efficacy of the composition is obviously reduced.
All possible combinations of the technical features of the above embodiments may not be described for the sake of brevity, but should be considered as within the scope of the present disclosure as long as there is no contradiction between the combinations of the technical features.
The above-mentioned embodiments only express several embodiments of the present invention, so as to understand the technical solutions of the present invention specifically and in detail, but not to be understood as the limitation of the protection scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. It should be understood that the technical solutions provided by the present invention, which are obtained by logical analysis, reasoning or limited experiments, are within the scope of the appended claims. Therefore, the protection scope of the patent of the invention is subject to the content of the appended claims, and the description can be used for explaining the content of the claims.
Claims (10)
1. The anti-aging composition is characterized by comprising the following components in parts by weight:
0.2 to 0.5 portion of madecassoside;
2 to 4 portions of sodium hyaluronate are digested; and
beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine 0.025 to 0.05;
the mass ratio of the madecassoside to the enzyme-cleaved sodium hyaluronate is (0.1 to 0.25): 1, and the mass ratio of the beta-alanyl hydroxyproline diaminobutyric acid benzylamine to the enzyme-cleaved sodium hyaluronate is (0.0125 to 0.025): 1.
2. The anti-aging composition according to claim 1, which consists of the following components in parts by mass:
0.4 to 0.5 portion of madecassoside;
2 to 4 portions of sodium hyaluronate are digested;
beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine 0.04 to 0.05 parts.
3. The anti-aging composition according to claim 2, which comprises the following components in parts by weight:
0.5 part of madecassoside;
4 parts of enzyme-digested sodium hyaluronate;
beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine 0.05 part.
4. The anti-aging composition of claim 1, wherein the mass ratio of the madecassoside to the enzymatically cleaved sodium hyaluronate is 0.1.
5. The anti-aging composition of any one of claims 1 to 4, wherein the mass ratio of β -alanyl hydroxyproline diaminobutyric acid benzylamine to the enzymatically cleaved sodium hyaluronate is 0.0125.
6. Use of the anti-aging composition as defined in any one of claims 1 to 5 in the preparation of skin care products or medicines.
7. A skin care product comprising the antiaging composition as claimed in any one of claims 1 to 5 and a base acceptable for use in a skin care product.
8. The skin care product of claim 7, wherein the skin care product is a cleansing product, a mask product, a cream, a serum, a toner, or an emulsion.
9. A toner, which is characterized by comprising a solvent, a humectant, a preservative and the anti-aging composition as defined in any one of claims 1 to 5.
10. A pharmaceutical product comprising the anti-aging composition according to any one of claims 1 to 5 and a pharmaceutically acceptable base.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210309547.4A CN114617792B (en) | 2022-03-28 | 2022-03-28 | Anti-aging composition, preparation method and application thereof, and anti-aging skin care product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210309547.4A CN114617792B (en) | 2022-03-28 | 2022-03-28 | Anti-aging composition, preparation method and application thereof, and anti-aging skin care product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114617792A CN114617792A (en) | 2022-06-14 |
| CN114617792B true CN114617792B (en) | 2022-11-18 |
Family
ID=81903865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210309547.4A Active CN114617792B (en) | 2022-03-28 | 2022-03-28 | Anti-aging composition, preparation method and application thereof, and anti-aging skin care product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114617792B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2728465A1 (en) * | 1994-12-23 | 1996-06-28 | Lvmh Rech | COSMETIC OR PHARMACEUTICAL COMPOSITION, IN PARTICULAR DERMATOLOGICAL, CONTAINING A SMELOPHYLLUM CAPENSE EXTRACT |
| CA2539712A1 (en) * | 2006-03-31 | 2007-09-30 | Laboratoires Dermo-Cosmetik Inc. | Anti-aging composition, kit and use |
| CN109953926A (en) * | 2019-04-09 | 2019-07-02 | 中美杜克(广州)护肤研究中心(普通合伙) | Five crease-resistant, Antiageing effect skin care item of dimension and preparation method thereof |
| CN113662881A (en) * | 2021-09-30 | 2021-11-19 | 水羊化妆品制造有限公司 | Composition for repairing sensitive skin, preparation method and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2791260B1 (en) * | 1999-03-26 | 2003-06-06 | Dior Christian Parfums | COSMETIC OR DERMATOLOGICAL COMPOSITIONS CONTAINING AT LEAST ONE SUBSTANCE FOR INCREASING THE FUNCTIONALITY AND / OR EXPRESSION OF CD44 MEMBRANE RECEPTORS OF SKIN CELLS |
| EP2706981B1 (en) * | 2011-05-10 | 2019-09-04 | Mary Kay Inc. | Cosmetic compositions |
| CN107334725A (en) * | 2017-08-08 | 2017-11-10 | 广州蜜妆生物科技有限公司 | A kind of anti-ageing American's flesh facial mask of Crithmum maritimum |
-
2022
- 2022-03-28 CN CN202210309547.4A patent/CN114617792B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2728465A1 (en) * | 1994-12-23 | 1996-06-28 | Lvmh Rech | COSMETIC OR PHARMACEUTICAL COMPOSITION, IN PARTICULAR DERMATOLOGICAL, CONTAINING A SMELOPHYLLUM CAPENSE EXTRACT |
| CA2539712A1 (en) * | 2006-03-31 | 2007-09-30 | Laboratoires Dermo-Cosmetik Inc. | Anti-aging composition, kit and use |
| CN109953926A (en) * | 2019-04-09 | 2019-07-02 | 中美杜克(广州)护肤研究中心(普通合伙) | Five crease-resistant, Antiageing effect skin care item of dimension and preparation method thereof |
| CN113662881A (en) * | 2021-09-30 | 2021-11-19 | 水羊化妆品制造有限公司 | Composition for repairing sensitive skin, preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 御泥坊微四百玻尿酸抗衰修护次抛精华液;国产普通化妆品备案信息;《https://hzpba.nmpa.gov.cn/gccx/chakan.html?prodId=989849158108053504&gb=G》;20211217;第1-6页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114617792A (en) | 2022-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111249209B (en) | Moisturizing repair cream and preparation method thereof | |
| US6468564B1 (en) | Topical compositions containing lotus for skin treatment | |
| US7700110B2 (en) | Skin firming and lifting compositions and methods of use | |
| US8460721B2 (en) | Active ingredient that stimulates the proliferation and/or activity of fibroblasts | |
| US20080108681A1 (en) | Use of allantoin as a pro-collagen synthesis agent in cosmetic compositions | |
| CN110013447B (en) | Cream for removing striae gravidarum and preparation method thereof | |
| US20070048245A1 (en) | Cosmetic composition to accelerate repair of functional wrinkles | |
| CN115137665B (en) | Composition with long-acting moisturizing and soothing effects and application thereof | |
| CN110833516B (en) | Polypeptide composition with moisturizing effect | |
| CN110302091B (en) | Composition containing nicotinamide adenine dinucleotide for resisting skin aging and preparation method and application thereof | |
| CN114177104A (en) | Anti-aging face cream | |
| CN114306165B (en) | Moisturizing composition and preparation method thereof | |
| CN108175740A (en) | It is a kind of that there is effectively repair cream of prevention and pregrant abdominal stretch marks-removing effect and preparation method thereof | |
| CN110721148A (en) | Multidirectional pulling and tightening polypeptide essence and preparation method thereof | |
| CN114246817A (en) | Wrinkle-removing composition and preparation method and application thereof | |
| CN110559206A (en) | Multidirectional anti-wrinkle polypeptide essence and preparation method thereof | |
| CN113952277A (en) | Microcrystalline peptide anti-wrinkle face cream and preparation method thereof | |
| CN113975192A (en) | Anti-aging composition and application thereof | |
| CN113332193A (en) | Composition and massage cream for preventing stretch marks | |
| CN112656731A (en) | Composition with red-repairing effect and preparation method and application thereof | |
| CN114617792B (en) | Anti-aging composition, preparation method and application thereof, and anti-aging skin care product | |
| CN110859758A (en) | Whitening anti-aging repair type medical cold compress patch and preparation method thereof | |
| CN115040448A (en) | Skin care product with enhanced anti-aging effect and preparation method thereof | |
| CN114557937A (en) | Freeze-dried powder and preparation method thereof | |
| CN111714393A (en) | Skin activating composition and activating emulsion thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |